ZA200500834B - Oral dosage form comprising a liquid active agent formulation and controlling release thereof by an expandable osmotic composition - Google Patents
Oral dosage form comprising a liquid active agent formulation and controlling release thereof by an expandable osmotic composition Download PDFInfo
- Publication number
- ZA200500834B ZA200500834B ZA200500834A ZA200500834A ZA200500834B ZA 200500834 B ZA200500834 B ZA 200500834B ZA 200500834 A ZA200500834 A ZA 200500834A ZA 200500834 A ZA200500834 A ZA 200500834A ZA 200500834 B ZA200500834 B ZA 200500834B
- Authority
- ZA
- South Africa
- Prior art keywords
- reservoir
- dosage form
- water
- oral dosage
- water impermeable
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 202
- 239000013543 active substance Substances 0.000 title claims description 112
- 239000007788 liquid Substances 0.000 title claims description 98
- 238000009472 formulation Methods 0.000 title claims description 96
- 230000003204 osmotic effect Effects 0.000 title claims description 91
- 239000006186 oral dosage form Substances 0.000 title claims description 67
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 178
- 239000000463 material Substances 0.000 claims description 159
- 239000002552 dosage form Substances 0.000 claims description 150
- 238000000034 method Methods 0.000 claims description 55
- 239000012528 membrane Substances 0.000 claims description 38
- 239000002861 polymer material Substances 0.000 claims description 38
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 28
- 108010010803 Gelatin Proteins 0.000 claims description 19
- 229920000159 gelatin Polymers 0.000 claims description 19
- 239000008273 gelatin Substances 0.000 claims description 19
- 235000019322 gelatine Nutrition 0.000 claims description 19
- 235000011852 gelatine desserts Nutrition 0.000 claims description 19
- 238000013270 controlled release Methods 0.000 claims description 17
- 239000004816 latex Substances 0.000 claims description 17
- 229920000126 latex Polymers 0.000 claims description 17
- 229920005989 resin Polymers 0.000 claims description 16
- 239000011347 resin Substances 0.000 claims description 16
- -1 polyethylene Polymers 0.000 claims description 14
- 239000002356 single layer Substances 0.000 claims description 13
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 12
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 12
- 229920000642 polymer Polymers 0.000 claims description 10
- 229920001577 copolymer Polymers 0.000 claims description 9
- OZJPLYNZGCXSJM-UHFFFAOYSA-N 5-valerolactone Chemical compound O=C1CCCCO1 OZJPLYNZGCXSJM-UHFFFAOYSA-N 0.000 claims description 8
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 8
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 8
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 8
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 8
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 8
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 8
- 229920001610 polycaprolactone Polymers 0.000 claims description 8
- 239000004632 polycaprolactone Substances 0.000 claims description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 7
- 229920003002 synthetic resin Polymers 0.000 claims description 7
- 150000004676 glycans Chemical class 0.000 claims description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 6
- 239000005017 polysaccharide Substances 0.000 claims description 6
- 239000004698 Polyethylene Substances 0.000 claims description 5
- 229920000573 polyethylene Polymers 0.000 claims description 5
- 229920002319 Poly(methyl acrylate) Polymers 0.000 claims description 4
- 239000004743 Polypropylene Substances 0.000 claims description 4
- 125000005396 acrylic acid ester group Chemical group 0.000 claims description 4
- 238000009833 condensation Methods 0.000 claims description 4
- 230000005494 condensation Effects 0.000 claims description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Substances OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims description 4
- 125000005397 methacrylic acid ester group Chemical group 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- LGRFSURHDFAFJT-UHFFFAOYSA-N phthalic anhydride Chemical class C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 claims description 4
- 238000006068 polycondensation reaction Methods 0.000 claims description 4
- 239000002952 polymeric resin Substances 0.000 claims description 4
- 229920001155 polypropylene Polymers 0.000 claims description 4
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 4
- 238000011068 loading method Methods 0.000 claims description 3
- 239000010410 layer Substances 0.000 description 31
- 239000002775 capsule Substances 0.000 description 29
- 239000011248 coating agent Substances 0.000 description 22
- 238000000576 coating method Methods 0.000 description 22
- 230000004888 barrier function Effects 0.000 description 19
- 230000008569 process Effects 0.000 description 19
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 18
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000005507 spraying Methods 0.000 description 11
- 230000000712 assembly Effects 0.000 description 9
- 238000000429 assembly Methods 0.000 description 9
- 229960005489 paracetamol Drugs 0.000 description 9
- 239000012530 fluid Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 229960003387 progesterone Drugs 0.000 description 6
- 239000000186 progesterone Substances 0.000 description 6
- 238000013461 design Methods 0.000 description 5
- 230000004907 flux Effects 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000005553 drilling Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000001746 injection moulding Methods 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 239000012669 liquid formulation Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229940081735 acetylcellulose Drugs 0.000 description 3
- 229920002301 cellulose acetate Polymers 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000009969 flowable effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000057 synthetic resin Substances 0.000 description 3
- 229920003169 water-soluble polymer Polymers 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 239000013061 administrable dose form Substances 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000003618 dip coating Methods 0.000 description 2
- 238000007598 dipping method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920001993 poloxamer 188 Polymers 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000005060 rubber Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000009966 trimming Methods 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000002174 Styrene-butadiene Substances 0.000 description 1
- SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- MTAZNLWOLGHBHU-UHFFFAOYSA-N butadiene-styrene rubber Chemical compound C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000011115 styrene butadiene Substances 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39277402P | 2002-06-28 | 2002-06-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200500834B true ZA200500834B (en) | 2006-04-26 |
Family
ID=30000933
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200500834A ZA200500834B (en) | 2002-06-28 | 2005-01-27 | Oral dosage form comprising a liquid active agent formulation and controlling release thereof by an expandable osmotic composition |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20040058000A1 (de) |
| EP (1) | EP1521570A1 (de) |
| JP (1) | JP2005533084A (de) |
| KR (1) | KR20050071376A (de) |
| CN (1) | CN1678291A (de) |
| AR (1) | AR040306A1 (de) |
| AU (1) | AU2003245738A1 (de) |
| CA (1) | CA2490412A1 (de) |
| IL (1) | IL166023A0 (de) |
| MX (1) | MXPA05000206A (de) |
| NO (1) | NO20050337L (de) |
| NZ (1) | NZ537492A (de) |
| TW (1) | TW200531708A (de) |
| WO (1) | WO2004002448A1 (de) |
| ZA (1) | ZA200500834B (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200518790A (en) * | 2003-07-31 | 2005-06-16 | Alza Corp | Osmotic engine & dosage form for controlled release of a liquid active agent formulation |
| WO2005030165A1 (en) * | 2003-09-26 | 2005-04-07 | Alza Corporation | Dosage form for controlled release of an active agent formulation |
| AU2004314693B2 (en) | 2003-09-26 | 2011-04-07 | Alza Corporation | Drug coating providing high drug loading and methods for providing the same |
| US8541026B2 (en) | 2004-09-24 | 2013-09-24 | Abbvie Inc. | Sustained release formulations of opioid and nonopioid analgesics |
| US20070014847A1 (en) * | 2005-07-05 | 2007-01-18 | Ahmed Salah U | Coated capsules and methods of making and using the same |
| FR2934805A1 (fr) | 2008-08-07 | 2010-02-12 | Inergy Automotive Systems Res | Procede pour fixer un accessoire dans un corps creux en matiere plastique lors de son moulage. |
| US20220409490A1 (en) * | 2020-03-02 | 2022-12-29 | Craft Health Pte Ltd | Method of manufacturing oral dosage forms for extended drug release |
| CN115490316B (zh) * | 2022-01-24 | 2023-09-12 | 成都理工大学 | 一种可再利用的地下水营养物质缓释胶囊体 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US36472A (en) * | 1862-09-16 | Cttlvebt | ||
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4077407A (en) * | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
| US4111202A (en) * | 1976-11-22 | 1978-09-05 | Alza Corporation | Osmotic system for the controlled and delivery of agent over time |
| US4200098A (en) * | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
| US5391381A (en) * | 1987-06-25 | 1995-02-21 | Alza Corporation | Dispenser capable of delivering plurality of drug units |
| US5034229A (en) * | 1988-12-13 | 1991-07-23 | Alza Corporation | Dispenser for increasing feed conversion of hog |
| US5223265A (en) * | 1992-01-10 | 1993-06-29 | Alza Corporation | Osmotic device with delayed activation of drug delivery |
| EP0804174A4 (de) * | 1993-07-21 | 1998-09-09 | Univ Kentucky Res Found | Mehrkammerhartkapseln mit kontrollierten abgabeeigenschaften |
| GB9326267D0 (en) * | 1993-12-23 | 1994-02-23 | Scherer Corp R P | Expulsion of material |
| US5614578A (en) * | 1994-10-28 | 1997-03-25 | Alza Corporation | Injection-molded dosage form |
| AU5175998A (en) * | 1996-11-15 | 1998-06-03 | Alza Corporation | Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems |
| US6245357B1 (en) * | 1998-03-06 | 2001-06-12 | Alza Corporation | Extended release dosage form |
| US6551613B1 (en) * | 1998-09-08 | 2003-04-22 | Alza Corporation | Dosage form comprising therapeutic formulation |
| US6174547B1 (en) * | 1999-07-14 | 2001-01-16 | Alza Corporation | Dosage form comprising liquid formulation |
| JP2002532406A (ja) * | 1998-12-17 | 2002-10-02 | アルザ・コーポレーション | 複合コーティングによる液体充填ゼラチンカプセルの放出制御システムへの変換 |
| CA2355860C (en) * | 1998-12-23 | 2010-03-30 | Alza Corporation | Dosage forms comprising porous particles |
| JP2003516345A (ja) * | 1999-12-09 | 2003-05-13 | アルザ・コーポレーション | 抗ウイルス剤 |
| US20030232078A1 (en) * | 2001-12-19 | 2003-12-18 | Dong Liang C. | Formulation & dosage form for the controlled delivery of therapeutic agents |
| CN1606432A (zh) * | 2001-12-19 | 2005-04-13 | 阿尔扎公司 | 用于增加亲水性大分子的口服生物利用度的制剂和剂型 |
-
2003
- 2003-06-27 JP JP2004518034A patent/JP2005533084A/ja not_active Withdrawn
- 2003-06-27 MX MXPA05000206A patent/MXPA05000206A/es not_active Application Discontinuation
- 2003-06-27 CN CNA038205696A patent/CN1678291A/zh active Pending
- 2003-06-27 NZ NZ537492A patent/NZ537492A/en not_active IP Right Cessation
- 2003-06-27 AR ARP030102346A patent/AR040306A1/es not_active Application Discontinuation
- 2003-06-27 IL IL16602303A patent/IL166023A0/xx unknown
- 2003-06-27 CA CA002490412A patent/CA2490412A1/en not_active Abandoned
- 2003-06-27 AU AU2003245738A patent/AU2003245738A1/en not_active Abandoned
- 2003-06-27 KR KR1020047021486A patent/KR20050071376A/ko not_active Application Discontinuation
- 2003-06-27 EP EP03739346A patent/EP1521570A1/de not_active Withdrawn
- 2003-06-27 WO PCT/US2003/020422 patent/WO2004002448A1/en active Application Filing
- 2003-06-27 US US10/608,305 patent/US20040058000A1/en not_active Abandoned
-
2004
- 2004-03-19 TW TW093107362A patent/TW200531708A/zh unknown
-
2005
- 2005-01-21 NO NO20050337A patent/NO20050337L/no not_active Application Discontinuation
- 2005-01-27 ZA ZA200500834A patent/ZA200500834B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004002448A1 (en) | 2004-01-08 |
| AU2003245738A1 (en) | 2004-01-19 |
| TW200531708A (en) | 2005-10-01 |
| CN1678291A (zh) | 2005-10-05 |
| JP2005533084A (ja) | 2005-11-04 |
| NZ537492A (en) | 2007-10-26 |
| IL166023A0 (en) | 2006-01-15 |
| US20040058000A1 (en) | 2004-03-25 |
| EP1521570A1 (de) | 2005-04-13 |
| MXPA05000206A (es) | 2005-12-05 |
| CA2490412A1 (en) | 2004-01-08 |
| AR040306A1 (es) | 2005-03-23 |
| KR20050071376A (ko) | 2005-07-07 |
| NO20050337L (no) | 2005-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6171618B1 (en) | Combination dosage form comprising cetirizine and pseudoephedrine | |
| CA1339079C (en) | Controlled release device with an impermeable coating having an orifice for release of drug | |
| CA2082740C (en) | Controlled release device | |
| RU2130311C1 (ru) | Лекарственные формы азитромицина с контролируемым высвобождением | |
| FI111516B (fi) | Hyödyllisen aineen kontrolloiduksi annostelemiseksi tarkoitettu väline | |
| KR920008701B1 (ko) | 비대칭막을 사용한 전달수단 | |
| EP0711146B1 (de) | Osmotische vorrichtung mit dampfdurchlaessiger beschichtung | |
| MXPA04006025A (es) | Formulacion y forma de dosificacion para el suministro controlado de agentes terapeuticos. | |
| ZA200500834B (en) | Oral dosage form comprising a liquid active agent formulation and controlling release thereof by an expandable osmotic composition | |
| HRP20030082A2 (en) | Hydrogel-driven drug dosage form | |
| EP1487420A1 (de) | Beschichtete pharmazeutische single-unit-retardformen auf polyvinylacetatbasis | |
| EP1667652B1 (de) | Verbesserte dosierform mit kontrollierter freisetzung mit stehantrieb | |
| ZA200601713B (en) | Permeation-resistant osmotic engine and dosage form for controlled release of a liquid active agent formulation | |
| US20040091538A1 (en) | Dosage form providing ascending release of liquid formulation | |
| US20050112190A1 (en) | Dosage form for controlled release of an active agent formulation | |
| US20040062799A1 (en) | Therapeutic composition and delivery system for administering drug |